Integer Holdings Co. (NYSE:ITGR) Stock Position Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 1.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 408,588 shares of the medical equipment provider’s stock after purchasing an additional 4,559 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Integer were worth $54,146,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of ITGR. Eagle Asset Management Inc. bought a new stake in shares of Integer during the 3rd quarter valued at about $14,403,000. Laurus Investment Counsel Inc. bought a new position in Integer in the 4th quarter worth about $5,422,000. New York State Common Retirement Fund lifted its stake in shares of Integer by 20.9% in the 4th quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider’s stock worth $30,820,000 after acquiring an additional 40,158 shares during the period. Bamco Inc. NY lifted its stake in shares of Integer by 17.4% in the 3rd quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock worth $33,069,000 after acquiring an additional 37,700 shares during the period. Finally, Jane Street Group LLC lifted its stake in Integer by 23.3% during the third quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after purchasing an additional 28,572 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ITGR. Benchmark increased their target price on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Citigroup increased their target price on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. KeyCorp boosted their price target on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Truist Financial boosted their price target on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Integer presently has a consensus rating of “Moderate Buy” and an average price target of $147.67.

Integer Stock Down 1.0 %

Integer stock opened at $118.41 on Friday. The firm has a market cap of $3.98 billion, a PE ratio of 35.24, a P/E/G ratio of 1.72 and a beta of 1.24. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The firm’s 50 day moving average price is $134.43 and its two-hundred day moving average price is $132.75. Integer Holdings Co. has a twelve month low of $107.11 and a twelve month high of $146.36.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. On average, research analysts predict that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.